Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who have had a diagnosis of plaque-type psoriasis for at least 6 months~* Patients who have plaque-type psoriasis covering at least 10% of the body~Exclusion Criteria:~* Patients must not have nonplaque forms of psoriasis~* Patients must not have current drug-induced psoriasis~* Patients must not be pregnant, nursing, or planning pregnancy (both men and women) within 18 months of enrollment~* Patients must not have had any previous treatment with infliximab or any therapeutic agent targeted at reducing TNF

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).